XOMA Royalty (XOMA) Reports Q3 Loss, Lags Revenue Estimates

Core Insights - XOMA Royalty reported a quarterly loss of $0.35 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.02, representing an earnings surprise of -1,650% [1] - The company generated revenues of $9.35 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 25.7%, but showing an increase from $7.2 million in the same quarter last year [2] - XOMA Royalty shares have increased by approximately 31.2% year-to-date, outperforming the S&P 500's gain of 16.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.15 on revenues of $13.46 million, and for the current fiscal year, it is $0.62 on revenues of $55.05 million [7] - The estimate revisions trend for XOMA Royalty was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which XOMA Royalty belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - VistaGen Therapeutics, another company in the same industry, is expected to report a quarterly loss of $0.51 per share, reflecting a year-over-year change of -21.4% [9]